Podcast: Download (14.8MB) | Embed
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance. Additional information can be found on the Company’s website at: www.lbti.com.
Lifeline competes in the money markets for funds to support the development and commercialization of its products. The cost of funds, for early stage companies like Lifeline, is expensive and the terms have been, and may continue to be, dilutive.